DOAC - Dosing Options in AntiCoagulation Prophylaxis
NCT07005024
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
996
Enrollment
OTHER
Sponsor class
Conditions
Cancer
VTE (Venous Thromboembolism)
Interventions
DRUG:
Apixaban 2.5 mg twice daily
DRUG:
Apixaban 5 mg once daily
DRUG:
No anticoagulation
Sponsor
University of Vermont